Clinical trial
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent…
NCT05269394 · Washington University School of Medicine, Other · Active, not recruiting
Key facts
| NCT number | NCT05269394 |
|---|---|
| Title | Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) |
| Official title | A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease |
| Acronym | DIAN-TU |
| Lead sponsor | Washington University School of Medicine, Other |
| Collaborators | Alzheimer's Association National Institute on Aging (NIA) NIH Accelerating Medicines Partnership (AMP) Eisai Inc. Industry |
| Status | Active, not recruiting |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimers Disease, Dementia, Familial |
| Intervention type | Drug |
| Interventions | E2814, Lecanemab, Matching Placebo (E2814) |
| Enrollment | 197 |
| Start date | Dec 22, 2021 |
| Primary completion | Apr 1, 2028 |
| Completion | Jul 1, 2028 |
| First posted | Mar 8, 2022 |
| Last update posted | Feb 13, 2026 |
| Countries | Argentina, Australia, Brazil, Canada, Colombia, France, Germany, Ireland, Italy, Japan, Mexico, Netherlands and 4 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: